Cargando…

PB1964: RELATIONSHIP BETWEEN SIRT1-7 AND SELECTED MIRNAS EXPRESSIONS IN MYELOMA/LYMPHOMA PATIENTS IN DIFFERENT REMISSION STATUS.

Detalles Bibliográficos
Autores principales:	Nowicki, M., Wierzbowska, A., Stec-Martyna, E., Kulczycka-Wojdala, D., Nowicki, G., Szmigielska-Kapłon, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431603/ http://dx.doi.org/10.1097/01.HS9.0000850692.22948.b4

Ejemplares similares

SIRT1-SIRT7 Expression in Patients with Lymphoproliferative Disorders Undergoing Hematopoietic Stem Cell Mobilization
por: Nowicki, Mateusz, et al.
Publicado: (2022)

PB1957: CIRCULATING MIRNA-16 AND MIRNA -21 EXPRESSION LEVELS IN MYELOMA; PRELIMINARY RESULTS.
por: Gkioka, A.-I., et al.
Publicado: (2022)

PB2453: FACTORS INFLUENCING AUTOLOGOUS PERIPHERAL BLOOD STEM CELL MOBILIZATION IN LYMPHOMA AND MULTIPLE MYELOMA
por: Longrong, Ran, et al.
Publicado: (2023)

PB2081: CYTOGENETICS OF MULTIPLE MYELOMA IN MOROCCO
por: Moutmir, Yasmine, et al.
Publicado: (2023)

PB1969: FUNCTIONAL CHARACTERIZATION OF SUSCEPTIBILITY LOCI TO MULTIPLE MYELOMA
por: Shokouhi, M., et al.
Publicado: (2022)

PB2430: EVALUATION OF OUTCOME AND SAFETY PROFILE IN HIGH-DOSE BEAM AND BEEAM CHEMOTHERAPY WITH SUBSEQUENT AUTOLOGOUS STEM CELL TRANSPLANTATION IN LYMPHOMA PATIENTS – SINGLE-CENTER EXPERIENCE
por: Krawiec, Kinga, et al.
Publicado: (2023)

PB1964: COMPARISON OF CLINICO-HEMATOLOGICAL PARAMETERS AND MOLECULAR AND CYTOGENETIC RESPONSE OF TWO BCR-ABL FUSION TRANSCRIPTS IN CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB
por: Baraa, Laabidi, et al.
Publicado: (2023)

PB1966: HEMOPOIETIC NICHE IMPAIRMENT IN TREATED MULTIPLE MYELOMA PATIENTS
por: Semenova, N. Y., et al.
Publicado: (2022)

PB1974: MULTIVARIATE SPECTRAL BIOTYPING OF EXTRAMEDULLARY MULTIPLE MYELOMA
por: Vlachová, M., et al.
Publicado: (2022)

PB1990: MULTIPLE MYELOMA IN THE ELDERLY: A MONOCENTRIC EXPERIENCE
por: Charfi, H., et al.
Publicado: (2022)

PB2278: INVESTIGATION ON THE STATUS OF INFECTION IN PATIENTS WITH MULTIPLE MYELOMA
por: Lan, D., et al.
Publicado: (2022)

PB1975: THE RESEARCH ON THE MECHANISM OF RRAD GENE IN MULTIPLE MYELOMA
por: Yi, C., et al.
Publicado: (2022)

PB1981: EFFICACY AND SAFETY OF DENOSUMAB IN PATIENTS WITH MULTIPLE MYELOMA
por: Bougherira, S., et al.
Publicado: (2022)

PB2015: YOUNG ADULTS WITH MULTIPLE MYELOMA – A SINGLE CENTER EXPERIENCE
por: Dos Santos Marques, I., et al.
Publicado: (2022)

PB2086: SIMULTANEOUS DIAGNOSIS OF MULTIPLE MYELOMA AND MYELODYSPLASIA: CASE REPORT.
por: Benabed, Khaled, et al.
Publicado: (2023)

PB2140: EVALUATION OF EARLY RELAPSE IN MULTIPLE MYELOMA (MM) PATIENTS
por: Gkioka, Annita-Ioanna, et al.
Publicado: (2023)

PB2156: CLINICAL AND PROGNOSTIC FACTORS IN MULTIPLE MYELOMA IN THE GOMEL REGION
por: Kozich, Zhanna, et al.
Publicado: (2023)

PB2157: AUTOSCT IN PATIENTS WITH MULTIPLE MYELOMA AND DIALYSIS-DEPENDENT NEPHROPATHY
por: Karimova, Ekaterina, et al.
Publicado: (2023)

PB1844: THROMBOTIC EVENTS DURING REMISSION INDUCTION OF ACUTE MYELOID LEUKEMIA – FREQUENCY AND RELATED FACTORS
por: Silva, W., et al.
Publicado: (2022)

PB1824: IMPACT OF DAY 15 BONE MARROW ASPIRATION ON PREDICTION OF COMPLETE REMISSION AND RELAPSE IN ACUTE MYELOID LEUKEMIA
por: Kharrat, R., et al.
Publicado: (2022)

PB1955: THE AGENDA FOR FUTURE MULTIPLE MYELOMA RESEARCH ACCORDING TO PATIENTS, CAREGIVERS, AND CLINICIANS
por: Fowler, S., et al.
Publicado: (2022)

PB2091: DISPARITIES IN ENROLMENT INTO MULTIPLE MYELOMA CLINICAL TRIALS BY SOCIOECONOMIC DEPRIVATION
por: Sridhar, Amrutha, et al.
Publicado: (2023)

PB2073: EVALUATION OF THE PLASMA METABOLOMIC PROFILE OF MGUS AND MULTIPLE MYELOMA PATIENTS
por: Ciesluk, Klaudia, et al.
Publicado: (2023)

PB2096: SELINEXOR COMBINED REGIMEN FOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE(EMD)
por: Zhong, Yuping, et al.
Publicado: (2023)

PB2126: RETROSPECTIVE REAL LIFE STUDY OF MULTIPLE MYELOMA STATUS AT DEATH.
por: Pérez, Mónica Fernández, et al.
Publicado: (2023)

PB2145: IMPACT OF A SIZE OF BONE PLASMACYTOMA ON THE COURSE OF MULTIPLE MYELOMA
por: Mamaeva, Elizaveta, et al.
Publicado: (2023)

PB1993: MULTIPLE MYELOMA BRAZILIAN REGISTER- HOW ABOUT THE TRANSPLANT ELIGIBLE PATIENTS?
por: Crusoe, E., et al.
Publicado: (2022)

PB2318: ACQUIRED WILLEBRAND SYNDROME REVEALING ASYMPTOMATIC MULTIPLE MYELOMA: A CASE REPORT
por: Chawad, W., et al.
Publicado: (2022)

PB2262: PEGFILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN POMALIDOMIDE-BASED TREATMENT
por: Cerchione, C., et al.
Publicado: (2022)

PB1968: EPIGENETIC AND GENETIC INVESTIGATION OF SOCS-1 GENE IN PATIENTS WITH MULTIPLE MYELOMA
por: Serin, I., et al.
Publicado: (2022)

PB2186: INTENSITY OF THE CONDITIONING REGIMEN AND TIMING OF AUTOGRAFT ENGRAFTMENT IN PATIENTS WITH MULTIPLE MYELOMA
por: Kostroma, I., et al.
Publicado: (2022)

PB2029: MULTIPLE MYELOMA AND SPINAL CORD COMPRESSION: THE EXPERIENCE OF THE HEMATOLOGY DEPARTMENT OF SFAX
por: Kallel, F., et al.
Publicado: (2022)

PB2090: SYSTEMATIC LITERATURE REVIEW OF PROGNOSTIC FACTORS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Kumar, Shaji, et al.
Publicado: (2023)

PB2094: APPLICATION OF WHOLE-GENOME SEQUENCING FOR COPY NUMBER ABNORMALITY IN MULTIPLE MYELOMA
por: LI, Jiali, et al.
Publicado: (2023)

PB2577: INFECTIONS AND THEIR RELATIONSHIP WITH EARLY MORTALITY IN PATIENTS NEWLY DIAGNOSED WITH MULTIPLE MYELOMA
por: Ontiveros-Austria, Juan Luis, et al.
Publicado: (2023)

PB2080: LOW DUP1 EXPRESSION PREDICTS POOR PROGNOSIS IN MULTIPLE MYELOMA
por: Lu, Jinfeng, et al.
Publicado: (2023)

PB2461: CONDITIONING REGIMEN AND SUBPOPULATION COMPOSITION OF AUTOGRAFT LYMPHOCYTES IN PATIENTS WITH MULTIPLE MYELOMA
por: Kostroma, Ivan, et al.
Publicado: (2023)

PB2153: IMPACT OF EXTRAMEDULLARY DISEASE IN PATIENTS WITH MULTIPLE MYELOMA: MULTICENTER RETROSPECTIVE ANALYSIS
por: e Sousa, Rita Costa, et al.
Publicado: (2023)

PB2139: MONITORING OLIGOSECRETORY MULTIPLE MYELOMA USING MALDI-TOF MASS SPECTROMETRY
por: Berlanga, Oscar, et al.
Publicado: (2023)

PB2107: EVOLUTION OF SELECTION CRITERIA FOR PHASE 3 CLINICAL TRIALS IN MULTIPLE MYELOMA.
por: Pérez, Ernesto, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g39k849s4igcartl6e9nbk6r55